Orion Biomarkers
Orion Biomarkers are tailored to enable spatial biomarker analysis with maximum flexibility. Choose from a range of labeled antibodies to generate Orion spatial biology data for multiplexed tissue imaging or create new reagents with easy-to-use conjugation kits.
Whole slide section of invasive colorectal adenocarcinoma
Type 1 Diabetes sample stained with Orion Biomarkers
Whole slide section liver with metastasized CRC
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
Orion Biomarker Portfolio
The Orion biomarker portfolio of conjugated antibodies and conjugation kits comprises more than 100 products spanning 60 unique biomarkers (human and mouse) and is growing rapidly.
Orion Biomarker enable the creation of multiple, unique panels applied to more than 15 unique tissue types, including whole tissue sections and tissue microarrays, and encompass multiple applications including Oncology and Autoimmunity indications.
All biomarkers are compatible with formalin-fixed paraffin-embedded (FFPE) or frozen tissue sections and use a simple staining process based on standard IHC / IF protocols. Orion Biomarker allow ultimate panel flexibility making it the undeniable choice for multiplexed spatial analysis.
Validated Orion Biomarkers
Select from a broad array of anti-human and anti-mouse primary antibodies directly conjugated to ArgoFluor™ dyes – bright, highly photostable and spectrally separated fluorophores. Directly conjugated antibodies enable a simple, one-step staining process and provide best-in-class reproducibility and biomarker quantitation. ArgoFluor dyes are also available as conjugation kits for customers who prefer to label their own reagents
Brochures
Product brochure: Orion Multiplex Imaging System for Spatial Biology
In this product brochure, discover the Orion™ novel technology and services platform offering fast path to whole slide, high-plex imaging. Combining speed and resolution, the Orion platform enables comprehensive phenotypic profiling and characterization of tissue architecture, tumor heterogeneity, and the immune response for whole sections in hours.
Orion spatial biology biomarkers
Explore the biomarkers for which RareCyte-validated reagents are available, including anti-human and anti-mouse biomarkers. Orion™ reagents are tailored to enable spatial biomarker analysis with maximum flexibility. Choose from their range of labeled antibodies to generate Orion spatial biology data for multiplexed tissue imaging, or create new reagents with easy-to-use conjugation kits. All reagents are compatible with formalin-fixed paraffin-embedded (FFPE) or frozen tissue sections and use a simple staining process based on standard IHC / IF protocols. With ease of staining and ultimate panel flexibility, Orion reagents are the convenient choice for multiplexed spatial analysis.
Orion Platform imaging for tumor-immune interactions
Deeper understanding of the intricacies between tumor microenvironments and immune cell infiltrates is critical for creation of next generation therapies. In this scientific poster, RareCyte presents a single-step 15-plex fluorescence immunohistochemistry (IHC) protocol using the Orion platform to analyze tumor microenvironments and immune cell phenotypes across multiple tumor types. The poster highlights a study aimed to enhance biomarker analysis by utilizing formalin-fixed paraffin-embedded (FFPE) tumor microarrays. The results demonstrate that the Orion platform can efficiently detect 15 distinct biomarkers on a single slide, surpassing traditional methods limited to 6 markers. The method offers significant workflow advantages, reducing tissue and signal loss, and potentially leading to better diagnostic and therapeutic outcomes by providing deeper insights into immune surveillance and mechanisms of resistance in various cancers.
Novel multianalyte assay has potential to transform cancer research and treatment
The use of protein biomarkers in oncology is growing rapidly and offers real hope to patients with hard-to-treat cancers
